Head-to-head · WeighScore
FuturHealth vs OrderlyMeds
The verdict
OrderlyMeds takes it — 72.4/100 to 65.6/100.
OrderlyMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OrderlyMeds is a telehealth provider selling compounded semaglutide and tirzepatide with no membership fees or hidden costs.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | OrderlyMeds |
|---|---|---|
| WeighScore | 65.6/100 | 72.4/100 |
| Grade | C | C |
| Scorecard rank | #215 | #78 |
| Semaglutide | $199/mo (compounded) | $74/mo (starting dose, 2-mo starter plan, new patients only, compounded) |
| Tirzepatide | Not disclosed | $299/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #78 · C
Strengths
- The starter rate and the standing rate are both published, so the step-up is visible before signing up
- No membership fees and no hidden costs, stated as such
- The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
- Brand-name routes are priced openly, at retail
Where it loses points
- The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
- Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
- Brand-name routes are priced at retail: Wegovy $1,839 and Zepbound $1,498
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.